TAKEDA PHARMACEUTICAL CO LTD

Takeda Pharmaceutical Company Limited has filed an amended version of its Articles of Incorporation, with the latest changes effective June 29, 2026. The updated articles outline the company's corporate name, head office location, and business purposes. Key provisions include the total authorized shares, unit share size, and the composition of the Board of Directors and Audit and Supervisory Committee.

Takeda Pharmaceutical Company Limited announced the results of its 150th Annual General Meeting of Shareholders held on June 24, 2026. Shareholders approved all proposed resolutions, including the appropriation of surplus for a year-end dividend of 100 JPY per share. The election of eight Directors who are not Audit and Supervisory Committee Members, three Directors who are Audit and Supervisory Committee Members, and one Substitute Director was also approved. Additionally, the payment of bonuses totaling up to 260 million JPY to eligible Directors was sanctioned.

Takeda Pharmaceutical Co. Ltd. released its 2026 Annual Integrated Report for fiscal year 2025, highlighting solid financial performance with $28.3 billion in revenue and $3.25 core EPS. The company made significant progress on its pipeline, preparing to launch three new products in the next 12 months and advancing late-stage assets. Takeda also reported substantial reductions in Scope 1, 2, and 3 GHG emissions, demonstrating commitment to its net-zero ambition by FY2040, and invested significantly in CSR and community programs.

Takeda Pharmaceutical Company Limited announced the official appointment of Julie Kim as its Representative Director, President, and Chief Executive Officer, concluding an 18-month CEO transition. Shareholders elected Ms. Kim as a new internal director, and she was subsequently appointed to the top leadership role by the Board of Directors. Former President & CEO Christophe Weber retired from the company. Additionally, the company announced new assignments for directors, including the election of three new external directors, further strengthening corporate governance with a majority of external directors on the Board and its key committees.

Takeda Pharmaceutical Company Limited announced the resolutions passed at its 150th Annual General Meeting of Shareholders. Key approvals included a year-end dividend of JPY 100 per share and the election of new and re-elected directors for both the Board and the Audit and Supervisory Committee. Shareholders also approved bonuses for non-Audit and Supervisory Committee Directors up to JPY 260 million.

Takeda Pharmaceutical announced the issuance of 16,989,076 ordinary shares and disposal of treasury shares under its Long-Term Incentive Plan (LTIP) for 10,557 employees outside of Japan. The shares, valued at 5,050 yen per share for a total of 85,794,833,800 yen, are intended to align employee interests with shareholders, attract and retain talent, and support risk mitigation. The plan includes Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) awards, with this issuance covering units vesting in 2026.

Takeda Pharmaceutical Co. Ltd. announced a revision to its consolidated financial statements for fiscal year 2025, which ended March 31, 2026. This revision follows a jury verdict on May 18, 2026, in the AMITIZA® (lubiprostone) antitrust litigation in the U.S. District Court for the District of Massachusetts, necessitating the recognition of provisions for legal proceedings. Despite the revisions to reported earnings, the company confirmed no changes to its Core financial results for FY2025, FY2026 financial forecast, or management guidance, and dividends remain unchanged.

Takeda Pharmaceutical Co Ltd revised its FY2025 financial results following a jury verdict against the company in the AMITIZA antitrust litigation. The company recorded an additional provision for legal proceedings of JPY 402.5 billion and recognized related tax benefits of JPY 58.4 billion. This revision does not impact Takeda's Core financial results, the FY2025 year-end dividend, or the FY2026 financial forecast and dividend. Takeda intends to pursue post-trial motions and an appeal.

Takeda Pharmaceutical Co Ltd announced the withdrawal of an old shelf registration statement and the filing of a new one in Japan. This new filing is for the issuance of new shares or disposition of treasury shares, up to JPY 240 billion, to facilitate its Long Term Incentive Plan (LTIP). The scheduled issue period is from June 9, 2026, to June 8, 2027, and the company expects approximately 1.1% share dilution for the fiscal year ending March 31, 2027, due to the LTIP.

Takeda Pharmaceutical disclosed JPY 129,266 million in impairment losses on intangible assets, including JPY 58,173 million for a cell therapy platform and JPY 31,877 million for ALUNBRIG due to reduced sales forecasts. The company also recorded JPY 70,818 million in restructuring expenses from an efficiency program. Additionally, Takeda acquired 11,824 thousand common shares for JPY 49,978 million. The filing detailed accounting policies, estimates for provisions, and ongoing legal proceedings.